Streetbeat News

BTCY

Biotricity, Inc.

https://www.biotricity.com

Industry

Medical - Devices

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Open

0.35

Mkt cap

7.7M

Volume

450

High

0.35

P/E Ratio

-0.20

52-wk high

1.67

Low

0.34

Div yield

N/A

52-wk low

0.19

Biotricity Inc. (NASDAQ:BTCY) has announced significant improvements in operational efficiency and margin performance due to upgrades in its AI Cloud platform. These enhancements are expected to improve the company's margins by 2-3% in the coming quarters, with further improvements anticipated. The company is on a path to profitability, leveraging its AI Cloud for better cardiac care diagnostics and operational efficiency.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:15 am

Biotricity Inc. (NASDAQ:BTCY) has launched HeartSecure, an at-home heart health screening service that provides immediate results, improving accessibility and affordability in cardiac care. This innovation addresses the delays in traditional cardiac screening and is expected to create new revenue streams for the company.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 11:35 am

Biotricity (NASDAQ:BTCY) reported a Q4 2024 adjusted EPS of $(0.47), missing the analyst estimate of $(0.36) by 30.56%. The company reported quarterly sales of $3.200 million, in line with estimates and a 16.79% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:26 pm

Biotricity reported Q4 revenue of $3.2 million, marking a 15.9% year-over-year increase. The company posted an EPS of $(0.47).

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:19 pm

Biotricity projects a year-end revenue growth exceeding 24% year-over-year, a decrease in loss from operations by over 40% year-over-year, and an improvement in margins by over 10% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 1:21 pm

Biotricity has launched a new direct-to-patient cardiac screening service, expanding its offerings in the healthcare sector.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 1:20 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include Lucy Scientific Discovery (LSDI), SINTX Techs (SINT), Nanoviricides (NNVC), Scorpius Holdings (SCPX), Onconetix (ONCO), and NRX Pharmaceuticals (NRXP). Key losers are Eyenovia (EYEN), 180 Life Sciences (ATNF), Omeros (OMER), Elicio Therapeutics (ELTX), Biotricity (BTCY), and T2 Biosystems (TTOO). Several of these movements are linked to recent earnings reports.

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 4:31 pm

Biotricity announces high demand for its Biotres Pro, a 3-channel patch-like ECG, expected to increase subscription prices by over 32% and revenue by up to 10% from sales to existing customers through 2025. The initial production run has sold out, with pre-orders for the next run scheduled to ship by the end of May.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:29 am

Biotricity Inc. has initiated a pilot program for cardiac monitoring across a hospital system that includes 9 hospitals and 10 clinics. This expansion into a significant healthcare network marks a pivotal step for Biotricity in demonstrating the effectiveness and scalability of their cardiac monitoring solutions.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 11:08 am

Biotricity Inc. has initiated a pilot program for cardiac monitoring in collaboration with a major hospital network. This move represents a significant step for Biotricity in expanding its reach and testing its technology in real-world healthcare settings. The partnership with a prominent hospital network could potentially enhance Biotricity's market presence and credibility in the medical technology sector.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:10 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.